financetom
Business
financetom
/
Business
/
Loar Likely to Benefit From Strong A&D Fundamentals in Q3, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Loar Likely to Benefit From Strong A&D Fundamentals in Q3, RBC Says
Nov 12, 2024 9:58 AM

12:41 PM EST, 11/12/2024 (MT Newswires) -- Loar Holdings ( LOAR ) is expected to gain in Q3 from strong Aerospace & Defense fundamentals, scarcity value, and a positive M&A landscape, RBC Capital Markets said in a report emailed Tuesday.

Loar ( LOAR ) will report its Q3 earnings on Wednesday, RBC said. "We expect the company to exceed 3Q24 expectations, but we expect any commentary on 2025 to be cautious, and considering the recent stock strength, we do not believe the [Q3] results will be a strong, positive catalyst," it added.

RBC's model estimates about 19% total revenue growth for Q3, with 11% organic growth driven by roughly 13% in business jet markets. The brokerage is optimistic about the segment's outlook, particularly with the potential for improvement under a potential Trump presidency.

RBC does not believe that Loar's ( LOAR ) performance has been hampered by a more stringent M&A regulatory process under the Biden administration. However, the firm expects M&A activity in the Aerospace & Defense sector to pick up into 2025. RBC sees potential upside from the company's acquisition of Applied Avionics.

"We believe the outlook for business jet will improve under a Trump presidency, and considering bizjet [original equipment manufacturer] services growth of [nearly] 16% in 3Q24, we view the elevated bizjet exposure for Loar ( LOAR ) as a positive," according to the note.

For Q3, RBC projects Loar's ( LOAR ) sales to reach $98.1 million, exceeding the $96.5 million consensus, with adjusted diluted EPS in line with consensus at $0.13.

RBC maintained an outperform rating on Loar ( LOAR ) and raised its price target to $100 from $80.

Shares of Loar ( LOAR ) were down 1.6% in recent Tuesday trading.

Price: 87.84, Change: -1.47, Percent Change: -1.65

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GE Aerospace's flight data app rapidly expands user base
GE Aerospace's flight data app rapidly expands user base
Oct 9, 2025
(Reuters) -The number of commercial pilots using GE Aerospace's flight data monitoring app, FlightPulse, has expanded rapidly from 40,000 a year ago to more than 60,000, and the company expects to exceed 70,000 by year-end. The app, the only one of its kind used commercially, allows pilots to evaluate their performances across various metrics compared to other pilots and learn...
PepsiCo beats quarterly market view on steady demand for healthier sodas
PepsiCo beats quarterly market view on steady demand for healthier sodas
Oct 9, 2025
(Reuters) -PepsiCo ( PEP ) beat Wall Street expectations for third-quarter revenue and profit on Thursday, buoyed by resilient demand for its energy drinks and healthier sodas in the United States, and named Walmart executive Steve Schmitt as its new finance head. Schmitt, who is currently the finance chief of Walmart U.S., will replace Jamie Caulfield in November. Caulfield retires...
Air travelers rethink plans as US government shutdown causes flight delays, cancellations 
Air travelers rethink plans as US government shutdown causes flight delays, cancellations 
Oct 9, 2025
NEW YORK (Reuters) -2025 has already been a bad year for the U.S. travel industry. The federal government shutdown is making it worse. Travelers are starting to cancel trips and avoid airports until U.S. lawmakers find a way to reopen the government, which may not happen for several more days or weeks. That means a longer stretch of time for...
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Oct 9, 2025
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. ( AKRO ) (“Akero”) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved